Publications
- Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. J Thorac Oncol. 2025 Mar;20(3):383-394. PubMed PMID: 39505259
- Partridge AH, Hyslop T, Rosenberg SM, Bennett AV, Drier S, Jonsson M, Shimada A, Li Y, Li Y, Lynch T, Frank E, Collyar D, Basila D, Pinto D, Weiss A, Wolf A, Norris K, Witten M, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Darai S, Carey L, Thompson A, Hwang ES. Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial. JAMA Oncol. 2025 Mar 1;11(3):300-309. PubMed PMID: 39665588
- Hwang ES, Hyslop T, Lynch T, Ryser MD, Weiss A, Wolf A, Norris K, Witten M, Grimm L, Schnitt S, Badve S, Factor R, Frank E, Collyar D, Basila D, Pinto D, Watson MA, West R, Davies L, Donovan JL, Shimada A, Li Y, Li Y, Bennett AV, Rosenberg S, Marks J, Winer E, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Carey LA, Thompson AM, Partridge AH. Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. JAMA. 2025 Mar 18;333(11):972-980. PubMed PMID: 39665585
Practice Locations
UCHealth Radiation Oncology - Anschutz Medical Campus1665 Aurora Ct
Aurora, CO 80045
720-848-0100
Specialty Information
Specialties- Radiation Oncology